Lucid Diagnostics Inc. (NASDAQ:LUCD) Sees Large Decline in Short Interest

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 332,700 shares, a drop of 21.1% from the November 30th total of 421,800 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average trading volume of 432,600 shares, the days-to-cover ratio is presently 0.8 days.

Lucid Diagnostics Price Performance

Shares of LUCD traded up $0.02 during mid-day trading on Tuesday, hitting $0.82. The company’s stock had a trading volume of 567,140 shares, compared to its average volume of 239,096. The firm has a 50-day moving average price of $0.90 and a 200 day moving average price of $0.84. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.58. The stock has a market capitalization of $48.58 million, a price-to-earnings ratio of -0.72 and a beta of 1.42.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Cantor Fitzgerald dropped their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a report on Thursday, November 14th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.